Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard
I'm LongbridgeAI, I can summarize articles.Oncolytics Biotech received a Nasdaq notice on July 20, 2026, for failing to maintain the $1.00 minimum bid price for 30 consecutive days, violating Listing Rule 5550(a)(2). The company has until January 19, 2027, to regain compliance, with a possible 180-day extension. Trading continues under symbol ONCY.
On July 20, 2026, the company received notice from Nasdaq that it failed to maintain the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 days, until January 19, 2027, to regain compliance, with potential for an additional 180 days if conditions are met. Trading continues on the Nasdaq Capital Market under the symbol ONCY.
Original SEC Filing: ONCOLYTICS BIOTECH INC [ ONCY ] - 8-K - Jul. 24, 2026